Foghorn Therapeutics Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Dec 2018 | — | $-39.3M | $40.6M |
| Jun 2019 | — | $-61.3M | — |
| Sep 2019 | — | $-73.8M | $21.5M |
| Dec 2019 | $11.0M | $-88.0M | $15.0M |
| Mar 2020 | — | $-101.2M | $3.4M |
| Jun 2020 | — | $-116.4M | $36.6M |
| Sep 2020 | $8.8M | $-133.3M | $74.6M |
| Dec 2020 | $19.7M | $146.2M | $92.8M |
| Mar 2021 | $20.0M | $125.2M | $66.4M |
| Jun 2021 | $20.0M | $104.2M | $125.2M |
| Sep 2021 | $20.0M | $81.0M | $57.8M |
| Dec 2021 | $0 | $96.9M | $101.1M |
| Mar 2022 | — | $72.4M | $213.6M |
| Jun 2022 | — | $47.6M | $61.2M |
| Sep 2022 | — | $24.3M | $87.6M |
| Dec 2022 | — | $112.0K | $52.2M |
| Mar 2023 | — | $-24.6M | $50.6M |
| Jun 2023 | — | $-49.4M | $57.7M |
| Sep 2023 | — | $-57.4M | $70.3M |
| Dec 2023 | — | $-77.2M | $80.3M |
| Mar 2024 | — | $-97.5M | $79.3M |
| Jun 2024 | — | $-14.3M | $138.9M |
| Sep 2024 | — | $-28.3M | $57.7M |
| Dec 2024 | — | $-45.5M | $55.5M |
| Mar 2025 | — | $-61.7M | $61.0M |
| Jun 2025 | — | $-76.7M | $72.6M |
| Sep 2025 | — | $-89.7M | $89.3M |
| Dec 2025 | — | $-108.5M | $80.9M |
| Mar 2026 | — | $-76.4M | $87.7M |
| Jun 2026 | — | $-81.0M | $68.1M |